ProCyte seeks US clearance for wound care product:
This article was originally published in Clinica
ProCyte (US) has filed for US FDA clearance of its Iamin gel wound dressing as a Class I device. Intended for use as a hydrogel, Iamin will compete in a market estimated to be worth $300 million this year. By the end of the decade the US wound management market is projected to reach $2,900 million.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.